Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
J Cancer Res Clin Oncol ; 149(11): 9425-9433, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37097392

ABSTRACT

PURPOSE: Okadaic acid class of tumor promoters are transformed into endogenous protein inhibitors of PP2A, SET, and CIP2A in human cancers. This indicates that inhibition of PP2A activity is a common mechanism of cancer progression in humans. It is important to study the roles of SET and CIP2A vis-à-vis their clinical significance on the basis of new information gathered from a search of PubMed. RESULTS AND DISCUSSION: The first part of this review introduces the carcinogenic roles of TNF-α and IL-1, which are induced by the okadaic acid class of compounds. The second part describes unique features of SET and CIP2A in cancer progression for several types of human cancer: (1) SET-expressing circulating tumor cells (SET-CTCs) in breast cancer, (2) knockdown of CIP2A and increased PP2A activity in chronic myeloid leukemia, (3) CIP2A and epidermal growth factor receptor (EGFR) activity in erlotinib sensitive- and resistant-non-small cell lung cancer, (4) SET antagonist EMQA plus radiation therapy against hepatocellular carcinoma, (5) PP2A inactivation as a common event in colorectal cancer, (6) prostate cancer susceptibility variants, homeobox transcription factor (HOXB13 T) and CIP2A T, and (7) SET inhibitor OP449 for pre-clinical investigation of pancreatic cancer. In the Discussion, the binding complex of SET is briefly introduced, and overexpression of SET and CIP2A proteins is discussed in relation to age-associated chronic inflammation (inflammaging). CONCLUSION: This review establishes the concept that inhibition of PP2A activity is a common mechanism of human cancer progression and activation of PP2A activity leads to effective anticancer therapy.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Liver Neoplasms , Lung Neoplasms , Male , Humans , Okadaic Acid , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinogens , Lung Neoplasms/drug therapy , Membrane Proteins/metabolism , Cell Line, Tumor , Intracellular Signaling Peptides and Proteins/genetics , Autoantigens/metabolism
2.
Toxins (Basel) ; 13(3)2021 03 01.
Article in English | MEDLINE | ID: mdl-33804551

ABSTRACT

The tumor necrosis factor-α (TNF-α)-inducing protein (tipα) gene family, comprising Helicobacter pylori membrane protein 1 (hp-mp1) and tipα, has been identified as a tumor promoter, contributing to H. pylori carcinogenicity. Tipα is a unique H. pylori protein with no similarity to other pathogenicity factors, CagA, VacA, and urease. American H. pylori strains cause human gastric cancer, whereas African strains cause gastritis. The presence of Tipα in American and Euro-Asian strains suggests its involvement in human gastric cancer development. Tipα secreted from H. pylori stimulates gastric cancer development by inducing TNF-α, an endogenous tumor promoter, through its interaction with nucleolin, a Tipα receptor. This review covers the following topics: tumor-promoting activity of the Tipα family members HP-MP1 and Tipα, the mechanism underlying this activity of Tipα via binding to the cell-surface receptor, nucleolin, the crystal structure of rdel-Tipα and N-terminal truncated rTipα, inhibition of Tipα-associated gastric carcinogenesis by tumor suppressor B-cell translocation gene 2 (BTG2/TIS21), and new strategies to prevent and treat gastric cancer. Thus, Tipα contributes to the carcinogenicity of H. pylori by a mechanism that differs from those of CagA and VacA.


Subject(s)
Antigens, Bacterial/metabolism , Bacterial Outer Membrane Proteins/metabolism , Bacterial Proteins/metabolism , Helicobacter Infections/microbiology , Helicobacter pylori/metabolism , Stomach Neoplasms/microbiology , Animals , Antigens, Bacterial/genetics , Bacterial Outer Membrane Proteins/genetics , Bacterial Proteins/genetics , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , Epithelial-Mesenchymal Transition , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter Infections/therapy , Helicobacter pylori/genetics , Helicobacter pylori/pathogenicity , Host-Pathogen Interactions , Humans , Immediate-Early Proteins/metabolism , Phosphoproteins/metabolism , RNA-Binding Proteins/metabolism , Risk Factors , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Stomach Neoplasms/prevention & control , Tumor Necrosis Factor-alpha/metabolism , Tumor Suppressor Proteins/metabolism , Nucleolin
3.
J Cancer Res Clin Oncol ; 144(12): 2339-2349, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30341686

ABSTRACT

PURPOSE: The okadaic acid class of tumor promoters, which are inhibitors of protein phosphatases 1 and 2A (PP1 and PP2A), induced tumor promotion in mouse skin, rat glandular stomach, and rat liver. Endogenous protein inhibitors of PP2A, SET and CIP2A, were up-regulated in various human cancers, so it is vital to review the essential mechanisms of tumor promotion by the okadaic acid class compounds, together with cancer progression by SET and CIP2A in humans. RESULTS AND DISCUSSION: The first part of this review introduces the okadaic acid class compounds and the mechanism of tumor promotion: (1) inhibition of PP1 and PP2A activities of the okadaic acid class compounds; (2) some topics of tumor promotion; (3) TNF-α gene expression as a central mediator in tumor promotion; (4) exposure to the okadaic acid class of tumor promoters in relation to human cancer. The second part emphasizes the overexpression of SET and CIP2A in cancer progression, and the anticancer activity of SET antagonists as follows: (5) isolation and characterization of SET; (6) isolation and characterization of CIP2A; (7) progression of leukemia with SET; (8) progression of breast cancer with SET and CIP2A; (9) progression of lung cancer with SET; (10) anti-carcinogenic effects of SET antagonists OP449 and FTY720; and also (11) TNF-α-inducing protein of Helicobacter pylori, which is a clinical example of the okadaic acid pathway. CONCLUSIONS: The overexpression of endogenous protein inhibitors of PP2A, SET and CIP2A, is tightly linked to the progression of various human cancers, as well as Alzheimer's disease.


Subject(s)
Autoantigens/metabolism , Histone Chaperones/metabolism , Membrane Proteins/metabolism , Neoplasms/etiology , Neoplasms/metabolism , Okadaic Acid/adverse effects , Protein Phosphatase 2/metabolism , Transcription Factors/metabolism , Animals , Autoantigens/genetics , Biomarkers, Tumor , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , DNA-Binding Proteins , Disease Progression , Environmental Exposure/adverse effects , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/chemistry , Gene Expression Regulation, Neoplastic , Helicobacter Infections/complications , Helicobacter Infections/microbiology , Helicobacter pylori/metabolism , Histone Chaperones/antagonists & inhibitors , Histone Chaperones/genetics , Humans , Intracellular Signaling Peptides and Proteins , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/genetics , Molecular Targeted Therapy , Neoplasms/drug therapy , Neoplasms/pathology , Okadaic Acid/chemistry , Protein Phosphatase 2/antagonists & inhibitors , Protein Phosphatase 2/genetics , Signal Transduction , Transcription Factors/antagonists & inhibitors , Transcription Factors/genetics , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
4.
Molecules ; 23(8)2018 Aug 18.
Article in English | MEDLINE | ID: mdl-30126206

ABSTRACT

The anticancer activity of immune checkpoint inhibitors is attracting attention in various clinical sites. Since green tea catechin has cancer-preventive activity in humans, whether green tea catechin supports the role of immune checkpoint inhibitors was studied. We here report that (-)-epigallocatechin gallate (EGCG) inhibited programmed cell death ligand 1 (PD-L1) expression in non⁻small-cell lung cancer cells, induced by both interferon (IFN)-γ and epidermal growth factor (EGF). The mRNA and protein levels of IFN-γ⁻induced PD-L1 were reduced 40⁻80% after pretreatment with EGCG and green tea extract (GTE) in A549 cells, via inhibition of JAK2/STAT1 signaling. Similarly, EGF-induced PD-L1 expression was reduced about 37⁻50% in EGCG-pretreated Lu99 cells through inhibition of EGF receptor/Akt signaling. Furthermore, 0.3% GTE in drinking water reduced the average number of tumors per mouse from 4.1 ± 0.5 to 2.6 ± 0.4 and the percentage of PD-L1 positive cells from 9.6% to 2.9%, a decrease of 70%, in lung tumors of A/J mice given a single intraperitoneal injection of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In co-culture experiments using F10-OVA melanoma cells and tumor-specific CD3+ T cells, EGCG reduced PD-L1 mRNA expression about 30% in F10-OVA cells and restored interleukin-2 mRNA expression in tumor-specific CD3+ T cells. The results show that green tea catechin is an immune checkpoint inhibitor.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , B7-H1 Antigen/antagonists & inhibitors , Catechin/pharmacology , Immunomodulation/drug effects , Tea/chemistry , Animals , Antineoplastic Agents, Phytogenic/chemistry , Catechin/chemistry , Cell Line, Tumor , Disease Models, Animal , Gene Expression , Humans , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , STAT1 Transcription Factor/metabolism , Signal Transduction/drug effects , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Xenograft Model Antitumor Assays
5.
Mol Cells ; 41(2): 73-82, 2018 Feb 28.
Article in English | MEDLINE | ID: mdl-29429153

ABSTRACT

Cancer preventive activities of green tea and its main constituent, (-)-epigallocatechin gallate (EGCG) have been extensively studied by scientists all over the world. Since 1983, we have studied the cancer chemopreventive effects of EGCG as well as green tea extract and underlying molecular mechanisms. The first part of this review summarizes ground-breaking topics with EGCG and green tea extract: 1) Delayed cancer onset as revealed by a 10-year prospective cohort study, 2) Prevention of colorectal adenoma recurrence by a double-blind randomized clinical phase II trial, 3) Inhibition of metastasis of B16 melanoma cells to the lungs of mice, 4) Increase in the average value of Young's moduli, i.e., cell stiffness, for human lung cancer cell lines and inhibition of cell motility and 5) Synergistic enhancement of anticancer activity against human cancer cell lines with the combination of EGCG and anticancer compounds. In the second part, we became interested in cancer stem cells (CSCs). 1) Cancer stem cells in mouse skin carcinogenesis by way of introduction, after which we discuss two subjects from our review on human CSCs reported by other investigators gathered from a search of PubMed, 2) Expression of stemness markers of human CSCs compared with their parental cells, and 3) EGCG decreases or increases the expression of mRNA and protein in human CSCs. On this point, EGCG inhibited self-renewal and expression of pluripotency-maintaining transcription factors in human CSCs. Human CSCs are thus a target for cancer prevention and treatment with EGCG and green tea catechins.


Subject(s)
Catechin/analogs & derivatives , Neoplasms/prevention & control , Neoplastic Stem Cells/drug effects , Tea/chemistry , Animals , Catechin/therapeutic use , Cell Movement/drug effects , Clinical Trials as Topic , Humans , Mice , Neoplasms/pathology , Phytotherapy/methods , Phytotherapy/trends
6.
J Cancer Res Clin Oncol ; 143(12): 2401-2412, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28942499

ABSTRACT

PURPOSE: Our previous experiments show that the main constituent of green-tea catechins, (-)-epigallocatechin gallate (EGCG), completely prevents tumor promotion on mouse skin initiated with 7,12-dimethylbenz(a)anthracene followed by okadaic acid and that EGCG and green tea extract prevent cancer development in a wide range of target organs in rodents. Therefore, we focused our attention on human cancer stem cells (CSCs) as targets of cancer prevention and treatment with EGCG. METHODS: The numerous reports concerning anticancer activity of EGCG against human CSCs enriched from cancer cell lines were gathered from a search of PubMed, and we hope our review of the literatures will provide a broad selection for the effects of EGCG on various human CSCs. RESULTS: Based on our theoretical study, we discuss the findings as follows: (1) Compared with the parental cells, human CSCs express increased levels of the stemness markers Nanog, Oct4, Sox2, CD44, CD133, as well as the EMT markers, Twist, Snail, vimentin, and also aldehyde dehydrogenase. They showed decreased levels of E-cadherin and cyclin D1. (2) EGCG inhibits the transcription and translation of genes encoding stemness markers, indicating that EGCG generally inhibits the self-renewal of CSCs. (3) EGCG inhibits the expression of the epithelial-mesenchymal transition phenotypes of human CSCs. (4) The inhibition of EGCG of the stemness of CSCs was weaker compared with parental cells. (5) The weak inhibitory activity of EGCG increased synergistically in combination with anticancer drugs. CONCLUSIONS: Green tea prevents human cancer, and the combination of EGCG and anticancer drugs confers cancer treatment with tissue-agnostic efficacy.


Subject(s)
Neoplasms/prevention & control , Neoplastic Stem Cells/drug effects , Animals , Biomarkers, Tumor/metabolism , Catechin/analogs & derivatives , Humans , Neoplasms/metabolism , Neoplasms/pathology , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology
7.
J Cancer Res Clin Oncol ; 143(8): 1359-1369, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28124725

ABSTRACT

PURPOSE: In 1988, we first reported the complete chemical structure of a new type of phorbol ester, abbreviated to DHPB, found in seed oil of Jatropha curcas L. (Saboodam in Thai) and its tumor-promoting activity on mouse skin. Although this seed oil contains toxic phorbol ester, it was planned to use it as a feasible renewable oil and the extracted seed cake as fertilizer. This utilization value opened a new science of Jatropha curcas. METHODS: The main experimental results are cited from our publications, and the relevant literature screened from journals and PubMed. RESULTS AND DISCUSSION: This paper begins with our original work on the structural elucidation of a new phorbol ester, 12-deoxy-16-hydroxyphorbol (DHPB): its tumor-promoting activity was compared with that of TPA. We think that it is timely to review the following research advances with Jatropha curcas, so numerous topics are classified as follows: (1) historical development of phorbol esters in seed oil; (2) toxicity of phorbol ester based on various bioassays; (3) degradation of phorbol ester; (4) a new pharmaceutical compound in seed; and (5) tumor promotion and progression with endogeneous tumor promoters in human carcinogenesis. The discovery of phorbol ester in seed oil raised awareness of the danger of public use of seed oil and seed cake in Thailand, and also indicated the necessity of discussing the concept of primary and tertiary cancer preventions. CONCLUSION: It is worthwhile to study the future benefits and cancer risks of globally distributed Jatropha curcas L.


Subject(s)
Carcinogenesis/drug effects , Neoplasms/drug therapy , Phorbol Esters/therapeutic use , Plant Oils/therapeutic use , Humans , Jatropha/chemistry , Neoplasms/pathology , Phorbol Esters/chemistry , Plant Oils/chemistry , Seeds/chemistry
8.
J Nutr Biochem ; 42: 7-16, 2017 04.
Article in English | MEDLINE | ID: mdl-28103535

ABSTRACT

(-)-Epigallocatechin gallate (EGCG), a green tea catechin, acts as a synergist with various anticancer drugs, including retinoids. Am80 is a synthetic retinoid with a different structure from all-trans-retinoic acid: Am80 is now clinically utilized as a new drug for relapsed and intractable acute promyelocytic leukemia patients. Our experiments showed that the combination of EGCG and Am80 synergistically induced both apoptosis in human lung cancer cell line PC-9 and up-regulated expressions of growth arrest and DNA damage-inducible gene 153 (GADD153), death receptor 5, and p21waf1 genes in the cells. To understand the mechanisms of synergistic anticancer activity of the combination, we gave special attention to the lysine acetylation of proteins. Proteomic analysis using nanoLC-ESI-MS/MS revealed that PC-9 cells treated with the combination contained 331 acetylated proteins, while nontreated cells contained 553 acetylated proteins, and 59 acetylated proteins were found in both groups. Among them, the combination increased acetylated-p53 and acetylated-α-tubulin through reduction of histone deacetylase (HDAC) activity in cytosol fraction, although the levels of acetylation in histones H3 or H4 did not change, and the combination reduced protein levels of HDAC4, -5 and -6 by 20% to 80%. Moreover, we found that a specific inhibitor of HDAC4 and -5 strongly induced p21waf1 gene expression, and that of HDAC6 induced both GADD153 and p21waf1 gene expression, which resulted in apoptosis. All results demonstrate that EGCG in combination with Am80 changes levels of acetylation in nonhistone proteins via down-regulation of HDAC4, -5 and -6 and stimulates apoptotic induction.


Subject(s)
Benzoates/pharmacology , Carcinoma, Non-Small-Cell Lung/drug therapy , Catechin/analogs & derivatives , Histone Deacetylase Inhibitors/pharmacology , Lung Neoplasms/drug therapy , Tetrahydronaphthalenes/pharmacology , Apoptosis/drug effects , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Catechin/pharmacology , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/genetics , Down-Regulation/drug effects , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , HL-60 Cells , Histone Deacetylase 6/antagonists & inhibitors , Histone Deacetylase 6/metabolism , Histone Deacetylases/metabolism , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Repressor Proteins/antagonists & inhibitors , Repressor Proteins/metabolism , Tea/chemistry , Transcription Factor CHOP/genetics
9.
Molecules ; 21(11)2016 Nov 18.
Article in English | MEDLINE | ID: mdl-27869750

ABSTRACT

Green tea catechin and green tea extract are now recognized as non-toxic cancer preventives for humans. We first review our brief historical development of green tea cancer prevention. Based on exciting evidence that green tea catechin, (-)-epigallocatechin gallate (EGCG) in drinking water inhibited lung metastasis of B16 melanoma cells, we and other researchers have studied the inhibitory mechanisms of metastasis with green tea catechins using biomechanical tools, atomic force microscopy (AFM) and microfluidic optical stretcher. Specifically, determination of biophysical properties of cancer cells, low cell stiffness, and high deformability in relation to migration, along with biophysical effects, were studied by treatment with green tea catechins. The study with AFM revealed that low average values of Young's moduli, indicating low cell stiffness, are closely associated with strong potential of cell migration and metastasis for various cancer cells. It is important to note that treatments with EGCG and green tea extract elevated the average values of Young's moduli resulting in increased stiffness (large elasticity) of melanomas and various cancer cells. We discuss here the biophysical basis of multifunctions of green tea catechins and green tea extract leading to beneficial effects for cancer prevention and treatment.


Subject(s)
Biochemical Phenomena , Catechin/pharmacology , Neoplasms/prevention & control , Tea/chemistry , Animals , Catechin/analogs & derivatives , Catechin/chemistry , Catechin/therapeutic use , Cell Movement/drug effects , Humans , Microfluidics , Microscopy, Atomic Force , Optical Phenomena , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use
10.
J Cancer Prev ; 20(1): 1-4, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25853098

ABSTRACT

Green tea is a daily beverage, a non-oxidized non-fermented product containing at least four green tea catechins. Considering our first results when repeated applications of (-)-epigallocatechin gallate (EGCG) prevented tumor promotion in mouse skin, we have continued to look at green tea as a possible cancer preventive agent. 1) The 10-year prospective cohort study by Drs. K. Nakachi and K. Imai revealed that drinking 10 Japanese-size cups (120 mL/cup) of green tea per day delayed cancer onset in humans by 7.3 years among females and by 3.2 years among males. The delay of cancer onset is of course significant evidence of primary cancer prevention in humans. 2) In collaboration with Dr. H. Moriwaki's group we successfully presented a prototype of tertiary cancer prevention showing that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (G.T.E), reduced recurrence of colorectal adenomas in polypectomy patients by 51.6% (from 31% to 15%). 3) In 1999, we first reported that the combination of green tea catechins and non-steroidal anti-inflammatory drugs showed synergistic anticancer effects in both in vitro and in vivo experiments, along with elucidation of the mechanism. 4) Further studies by other investigators have revealed that various combinations of EGCG or green tea extract and anticancer compounds inhibit tumor volume in xenograft mouse models implanted with various human cancer cell lines. Green tea is a cancer preventive, and green tea catechins act as synergists with anticancer compounds.

11.
J Cancer Res Clin Oncol ; 141(9): 1511-22, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25544670

ABSTRACT

PURPOSE: In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6% in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs. RESULTS AND DISCUSSION: The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153-DR5-TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3%. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage. CONCLUSION: Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Catechin/analogs & derivatives , Catechin/pharmacology , Animals , Catechin/administration & dosage , Cell Line, Tumor , Drug Screening Assays, Antitumor , Drug Synergism , Humans , Tea/chemistry , Xenograft Model Antitumor Assays
12.
J Cancer Res Clin Oncol ; 140(5): 689-99, 2014 May.
Article in English | MEDLINE | ID: mdl-24469254

ABSTRACT

PURPOSE: Cell-surface nucleolin in human gastric cancer cell lines is a receptor for TNF-α-inducing protein (Tipα) of Helicobacter pylori. The binding complex of nucleolin and Tipα is internalized into the cells and then induces tumor progression of human gastric cancer. Surface nucleolin is also a receptor of human immunodeficiency virus-1, and the anti-HIV pseudopeptide (HB-19) showed anti-carcinogenic activity in vivo. Surface nucleolin has dual functions depending on the ligands: In order to understand the mechanisms of surface nucleolin, it is necessary to review surface nucleolin and its relation to carcinogenic ligands and anti-carcinogenic ligands. Other ligands can be grouped among disease-related ligands, which is an important new topic for the prevention of various ailments. RESULTS AND DISCUSSION: This paper mainly deals with two ligands of surface nucleolin, Tipα and pseudopeptide HB-19. The binding complex of nucleolin and Tipα induces expression of TNF-α and chemokine genes and activates NF-κB in gastric cancer cells of humans and mice. However, when human gastric cancer cell line MKN-1 was transfected with nucleolin-targeted siRNA, the result was inhibition of cell migration and elongation induced by Tipα. The amount of surface nucleolin was reduced in membrane fraction of the nucleolin knockdown MKN-1 cells, but the amount of nucleolin in the cytosol or nuclear fractions of the cells did not change. The results indicate that surface nucleolin acts as a carcinogenic mediator for Tipα of H. pylori. In contrast, both the viral external envelop glycoprotein gp120 of HIV and the anti-HIV pseudopeptide HB-19 bind to surface nucleolin. Through this binding, treatment with HB-19 inhibited tumor development in human breast cancer cell line MDA-MB-231 and rhabdoid tumor cell line derived from Wilms's tumor in xenograft nude mouse models. The results show that surface nucleolin acts as an anti-carcinogenic mediator for HB-19. CONCLUSION: Based on these discrete functions of surface nucleolin, the binding complex of carcinogenic ligands and surface nucleolin seems to be competing with that of anti-carcinogenic ligands and surface nucleolin. Moreover, carcinogenic ligands derived from endogenous sources play a significant role in human cancer development, and the interaction of surface nucleolin with disease-related ligands will be a new research subject for the prevention and treatment of various ailments.


Subject(s)
Carcinogenesis/genetics , Peptides/metabolism , Phosphoproteins/metabolism , RNA-Binding Proteins/metabolism , Stomach Neoplasms/genetics , Tumor Necrosis Factor-alpha/genetics , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cell Line, Tumor , Cell Movement/genetics , HIV-1/genetics , HIV-1/metabolism , Helicobacter pylori/genetics , Humans , Ligands , Macromolecular Substances/chemistry , Macromolecular Substances/metabolism , Mice , Peptides/chemistry , Peptides/genetics , Phosphoproteins/genetics , Protein Binding , RNA-Binding Proteins/genetics , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Tumor Necrosis Factor-alpha/biosynthesis , Nucleolin
13.
Biochem Biophys Res Commun ; 443(1): 1-6, 2014 Jan 03.
Article in English | MEDLINE | ID: mdl-24269590

ABSTRACT

Cell motility and cell stiffness are closely related to metastatic activity of cancer cells. (-)-Epigallocatechin gallate (EGCG) has been shown to inhibit spontaneous metastasis of melanoma cell line into the lungs of mice, so we studied the effects of EGCG on cell motility, cell stiffness, and expression of vimentin and Slug, which are molecular phenotypes of epithelial-mesenchymal transition (EMT). Treatments of human non-small cell lung cancer cell lines H1299 and Lu99 with 50 and 100 µM EGCG reduced cell motility to 67.5% and 43.7% in H1299, and 71.7% and 31.5% in Lu99, respectively in in vitro wound healing assay. Studies on cell stiffness using atomic force microscope (AFM) revealed that treatment with 50 µM EGCG increased Young's modulus of H1299 from 1.24 to 2.25 kPa and that of Lu99 from 1.29 to 2.28 kPa, showing a 2-fold increase in cell stiffness, i.e. rigid elasticity of cell membrane. Furthermore, treatment with 50 µM EGCG inhibited high expression of vimentin and Slug in the cells at a leading edge of scratch. Methyl-ß-cyclodextrin, a reagent to deplete cholesterol in plasma membrane, showed inhibition of EMT phenotypes similar that by EGCG, suggesting that EGCG induces inhibition of EMT phenotypes by alteration of membrane organization.


Subject(s)
Antineoplastic Agents/pharmacology , Catechin/analogs & derivatives , Cell Movement/drug effects , Epithelial-Mesenchymal Transition/drug effects , Neoplasm Metastasis/prevention & control , Transcription Factors/antagonists & inhibitors , Vimentin/antagonists & inhibitors , Animals , Catechin/pharmacology , Cell Line, Tumor , Cell Membrane/chemistry , Cell Membrane/drug effects , Cholesterol/metabolism , Elastic Modulus/drug effects , Humans , Mice , Microscopy, Atomic Force , Snail Family Transcription Factors , beta-Cyclodextrins/pharmacology
14.
Cancer Sci ; 105(2): 143-9, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24313817

ABSTRACT

The concept of cancer and inflammation has a long history. Virchow's irritation theory based on human cancer engendered the essential role of inflammation in carcinogenesis. Drs. Yamagiwa and Ichikawa first published a comprehensive paper entitled "Experimental study on the pathogenesis of epithelial tumors" (I report) in 1915 in German, and went on to publish five more reports (1915-1924) under the same title. They succeeded in demonstrating that inflammation is an important carcinogenic factor, and the mechanisms are now being investigated by numerous scientists all over the world. In order to introduce Yamagiwa's work to modern cancer researchers, the essentials of their six reports have been translated into English as a short review. Scientists' comments on Yamagiwa's contribution are attached by way of introduction.


Subject(s)
Carcinogenesis/pathology , Inflammation/pathology , Neoplasms/etiology , Neoplasms/pathology , Animals , Epithelial Cells/pathology , Humans
15.
Int J Cancer ; 134(10): 2373-82, 2014 May 15.
Article in English | MEDLINE | ID: mdl-24249671

ABSTRACT

Helicobacter pylori strains produce tumor necrosis factor-α (TNF-α)-inducing protein, Tipα as a carcinogenic factor in the gastric epithelium. Tipα acts as a homodimer with 38-kDa protein, whereas del-Tipα is an inactive monomer. H. pylori isolated from gastric cancer patients secreted large amounts of Tipα, which are incorporated into gastric cancer cells by directly binding to nucleolin on the cell surface, which is a receptor of Tipα. The binding complex induces expression of TNF-α and chemokine genes, and activates NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). To understand the mechanisms of Tipα in tumor progression, we looked at numerous effects of Tipα on human gastric cancer cell lines. Induction of cell migration and elongation was found to be mediated through the binding to surface nucleolin, which was inhibited by the nucleolin-targeted siRNAs. Tipα induced formation of filopodia in MKN-1 cells, suggesting invasive morphological changes. Tipα enhanced the phosphorylation of 11 cancer-related proteins in serine, threonine and tyrosine, indicating activation of MEK-ERK signal cascade. Although the downregulation of E-cadherin was not shown in MKN-1 cells, Tipα induced the expression of vimentin, a significant marker of the epithelial-mesenchymal transition (EMT). It is of great importance to note that Tipα reduced the Young's modulus of MKN-1 cells determined by atomic force microscopy: This shows lower cell stiffness and increased cell motility. The morphological changes induced in human gastric cancer cells by Tipα are significant phenotypes of EMT. This is the first report that Tipα is a new inducer of EMT, probably associated with tumor progression in human gastric carcinogenesis.


Subject(s)
Bacterial Proteins/pharmacology , Epithelial-Mesenchymal Transition/drug effects , Helicobacter pylori/metabolism , Bacterial Proteins/genetics , Blotting, Western , Cell Line, Tumor , Cell Movement/drug effects , Cell Shape/drug effects , Dose-Response Relationship, Drug , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , MAP Kinase Kinase 1/metabolism , Microscopy, Atomic Force , Phosphoproteins/genetics , Phosphoproteins/metabolism , Phosphorylation/drug effects , Pseudopodia/drug effects , RNA Interference , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Recombinant Proteins/pharmacology , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Tumor Necrosis Factor-alpha/pharmacology , Nucleolin
16.
J Cancer Res Clin Oncol ; 139(10): 1603-14, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23756937

ABSTRACT

PURPOSE: The classic two-stage chemical carcinogenesis in rodents is not directly linked to multistage carcinogenesis in humans. In light of our findings that tumor necrosis factor-α (TNF-α) is an endogenous tumor promoter and that TNF-α-inducing protein (Tipα) of Helicobacter pylori stimulates progression of cancer and epithelial-mesenchymal transition, we think it is necessary to re-examine the concept of tumor promoter, from chemicals to inflammatory proteins. TOPICS AND RESULTS: This paper begins with "inflammation," discovered by Virchow, studies of Yamagiwa and Tsutsui, and briefly reviews numerous topics, such as (1) the classic concept of tumor promoter, (2) tumor promotion on mouse skin induced by protein kinase C activators and okadaic acid class compounds, (3) organ specificity of tumor promoters, presenting numerous tumor promoters in various organs, (4) unique tumor promotion induced by inhibitors of protein phosphatases 1 and 2A in mouse skin, rat glandular stomach, and rat liver, (5) the significant role of TNF-α in tumor-promoting inflammation, (6) progression induced by Tipα of H. pylori, and (7) enhancement of cancer treatment efficacy with the combination of anticancer drugs and green tea catechins, to inhibit tumor-promoting inflammation. CONCLUSION: Human cancer development involves both durable genetic changes caused by carcinogens and proinflammatory cytokines, and simultaneous inflammation in progression induced by proinflammatory cytokines and chemokines.


Subject(s)
Carcinogens/pharmacology , Inflammation Mediators/physiology , Skin Neoplasms/chemically induced , Animals , Anticarcinogenic Agents/pharmacology , Catechin/analogs & derivatives , Catechin/pharmacology , Gastrointestinal Neoplasms/etiology , Gastrointestinal Neoplasms/immunology , Gastrointestinal Neoplasms/prevention & control , Helicobacter Infections/complications , Helicobacter Infections/immunology , Humans , Inflammation/chemically induced , Neoplasms, Experimental/chemically induced , Neoplasms, Experimental/enzymology , Neoplasms, Experimental/immunology , Okadaic Acid/pharmacology , Organ Specificity , Skin Neoplasms/enzymology , Skin Neoplasms/immunology
18.
J Cancer Res Clin Oncol ; 138(8): 1259-70, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22699930

ABSTRACT

PURPOSE: Drinking green tea daily is part of Japanese culture, and various studies have revealed that green tea is a cancer preventive. We here review our progress in cancer prevention with green tea on 12 main topics, from basic to clinical level. TOPICS AND METHODS: Biochemical and biological studies of green tea catechins, a prospective cohort study, preclinical safety trials with tablets of green tea extract, double-blind randomized clinical phase II prevention trial for recurrence of colorectal adenomas, and synergistically enhanced inhibition by the combination of green tea catechins and anticancer drugs. All results were significant, including human studies with informed consent. RESULTS: Drinking 10 Japanese-size cups of green tea per day delayed the cancer onset of humans 7 years for females. For tertiary cancer prevention, consuming 10 cups of green tea per day fortified by green tea tablets, 50 %, significantly prevented the recurrence of colorectal adenomas. A minimum effective amount of green tea catechins for cancer prevention was found in humans. In addition, the combination of green tea catechins and anticancer drugs engendered a new cancer therapeutic strategy. CONCLUSION: The consumption of 10 Japanese-size cups of green tea per day is a significant factor in primary cancer prevention for the general population, and the preventive effect on recurrence of colorectal adenomas in patients is vital evidence in tertiary cancer prevention.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Catechin/therapeutic use , Neoplasms/prevention & control , Tea/chemistry , Animals , Female , Humans , Male , Phytotherapy/methods , Phytotherapy/trends , Plant Extracts/therapeutic use
19.
Cancer Lett ; 324(2): 119-25, 2012 Nov 28.
Article in English | MEDLINE | ID: mdl-22626556

ABSTRACT

Green tea is now an acknowledged cancer preventive in Japan. Based on evidence that colorectal adenomas and prostate cancer in humans have been prevented, we review here the concept that the combination of anticancer drugs with green tea catechin synergistically induces apoptosis of human cancer cells, inhibits tumor formation in mice, and enhances inhibition of tumor growth in xenograft mouse models. As a molecular mechanism by the combination, the induction of growth arrest and DNA damage-inducible 153 (GADD153, CHOP) gene expression is discussed in relation to death receptor 5 and TRAIL-apoptotic pathway. The combination of anticancer drugs with green tea could be a new cancer therapeutic strategy in humans.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Neoplasms/drug therapy , Tea , Animals , Apoptosis/drug effects , Catechin/analogs & derivatives , Catechin/pharmacology , Cell Line, Tumor , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/pathology , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , TNF-Related Apoptosis-Inducing Ligand/metabolism , Transcription Factor CHOP/genetics , Transcription Factor CHOP/metabolism , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
20.
Cancer Lett ; 322(2): 133-8, 2012 Sep 28.
Article in English | MEDLINE | ID: mdl-22459353

ABSTRACT

TNF-α-inducing protein (Tipα) is a unique carcinogenic factor of Helicobacter pylori, which is secreted into culture broth. The biological activities of Tipα and deletion mutant were studied. Tipα protein specifically binds to cell-surface nucleolin and then enters the gastric cancer cells, where TNF-α and chemokine gene expressions are induced by NF-κB activation. Nucleolin localizes on the surface of gastric cancer cells, and interaction between Tipα and cell-surface nucleolin causes a cancer-oriented microenvironment that increases the risk of gastric cancer. This paper discusses a new mechanism of gastric cancer development with H. pylori and provides a new preventive strategy.


Subject(s)
Bacterial Proteins/metabolism , Stomach Neoplasms/etiology , Amino Acid Sequence , Animals , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Cell Transformation, Neoplastic , Chemokines/genetics , Gene Expression , Humans , Molecular Sequence Data , Molecular Targeted Therapy , NF-kappa B/metabolism , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/metabolism , Protein Binding , Protein Structure, Tertiary , RNA-Binding Proteins/antagonists & inhibitors , RNA-Binding Proteins/metabolism , Stomach Neoplasms/metabolism , Stomach Neoplasms/therapy , Tumor Necrosis Factor-alpha/genetics , Nucleolin
SELECTION OF CITATIONS
SEARCH DETAIL
...